Triptorelin is considered the most potent LH‐RH agonist achieving the lowest mean testosterone levels and demonstrating effectiveness as an androgen deprivation therapy (ADT) for PCa.7, 8. This evidence concerns the gene GNRH1 and posterior cortical atrophy.